We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Why I’m avoiding these 3 FTSE 100 stocks in 2020

G A Chester sees different issues with these three FTSE 100 (INDEXFTSE:UKX) stocks, but valuations are the acid test.

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

There are a number of FTSE 100 stocks I think could disappoint investors in 2020. Among them are AstraZeneca (LSE: AZN), St. James’s Place (LSE: STJ) and Scottish Mortgage Investment Trust (LSE: SMT). Here’s why I’m avoiding these three.

Dubious core strength

AstraZeneca’s management has maintained the core earnings per share (EPS) guidance it gave at the start of the year of $3.50-$3.70 for 2019. At the midpoint and current exchange rates, this gives a price-to-earnings (P/E) ratio of 26.5 at a share price of 7,300p.

Should you buy AstraZeneca Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

This is a huge premium to Footsie pharma peers GlaxoSmithKline and Hikma Pharmaceuticals, which trade at P/Es of 14.4 and 17.7 respectively. Furthermore, I’d argue AZN’s core EPS, on which the 26.5 P/E is based, grossly overstates its real core earnings, and that the true P/E is nearer a jaw-dropping 40.

This is because I exclude one-off profits from the divestment of non-core assets, which can’t go on forever but which AZN books as core operating profit. I also include legal costs (a routine expense in operating a big pharma company), which AZN excludes. AZN looks overvalued to me on its own core EPS measure, but grossly overvalued on what I consider its true core earnings.

Iffy business model

I’m avoiding wealth manager St. James’s Place on a view that it’s not only overvalued, but also has an iffy business model, and will have to change, with profit-margin-sapping consequences.

At a share price of around 1,100p, STJ’s P/E is 32.4 on forecast EPS of 34p for 2019. This earnings multiple is far too high, in my opinion. Furthermore, a valuation of more than 3% of funds under management (FUM) has proved a trusty indicator of overvaluation, in my experience. With a market capitalisation of £5.88bn, and FUM of £112.82bn, STJ is valued at 5.2% of FUM.

The company’s management fees and exit fees are excessive, in my view. Investors haven’t worried too much about this, seeing their portfolios increase in value over the last 10 years of rising markets, but are likely to pay a lot more attention in a downturn. Furthermore, with investors generally becoming a lot savvier about the corrosive effect of fees on returns, I think STJ will ultimately have to reset its margins.

Bonkers

It’s a peculiar and persistent feature of the UK stock market that some investment trust or another will rise from the FTSE 250 to the FTSE 100. However, no trust in history has gained sufficient critical mass to maintain its position in the top index.

Scottish Mortgage is the current representative in the FTSE 100. It’s achieved its status by a combination of high returns (471% over the last 10 years) and increasing popularity with investors (taking its shares to a premium to net asset value (NAV)).

The company has surfed on the outperformance of the US market and tech sector, holding a number of the so-called FAANG stocks, and the likes of Illumina and Tesla. The managers of the trust have borrowed money to gear returns (gearing is currently 9%), and remain optimistic on the outlook.

Personally, I think the valuations of many of the underlying holdings are bonkers. I fear a de-rating, SMT’s NAV dropping, gearing working negatively, and the shares moving to a wide discount to NAV. If so, SMT will become another in the long history of investment trusts failing to maintain a place in the FTSE 100.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline and Tesla. The Motley Fool UK has recommended AstraZeneca and Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

Forget Rolls-Royce shares, this incredible penny stock is forecast to soar 762%!

Faron Pharmaceuticals shares are forecast to gain 762% in the coming 12 months, mimicking the recent performance of Rolls-Royce shares.

Read more »

Close-up of children holding a planet at the beach
Investing Articles

How to turn a £20,000 ISA into a £20-a-day passive income stream

Does earning regular passive income seem out of your grasp? Break it down to a simple, step-by-step plan, and it’s…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

3 UK shares tipped to soar 100% (or more) in the next 12 months

Mark Hartley assesses the growth potential of three lesser-known UK shares with optimistic broker targets. Could they double in value…

Read more »

Curtains, happy woman and thinking of future in home, planning and reflection of mindset with view. Window, smile and African girl with vision, ideas and dream for morning inspiration in living room.
Investing Articles

Up 36% in 3 months! Is this beaten-down FTSE 100 growth stock finally ready to rocket?

Sensing a bargain, Harvey Jones snapped up this growth stock whose shares have fallen by half. Suddenly things are starting…

Read more »

Image of happy young people man and woman in basic clothing thinking and touching chin while looking aside isolated over yellow background
Investing Articles

Up 147% with a 6%+ yield and dirt-cheap P/E – yet this FTSE 100 dividend stock still flies under the radar

Harvey Jones flags up an impressive UK-listed dividend stock that may have passed some investors by. What's driving its stellar…

Read more »

Mining truck in a coal open pit mine
Investing Articles

Forget SpaceX! 2 top growth stocks to consider buying in August

Hunting for growth stocks to buy? Ben McPoland spotlights a tech share from across the pond and another in the…

Read more »

Investing Articles

£1,500 buys 447 shares in this UK stock that’s trouncing the FTSE 100

The FTSE 100's up nicely in the past year, but my favourite growth stock from the FTSE 250 has blown…

Read more »

Electric cars charging at a charging station
Investing Articles

Is this $7 stock the next Tesla?

After skyrocketing over the past decade-and-a-half, everyone has heard of Tesla stock. But this $7 upstart is still under the…

Read more »